NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Avalo Therapeutics, Inc. AVTX
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$59,000
▼ 86.6% vs FY2024
EPS · FY25
$-5.84
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-72.4%
Net margin · FY25
-132642.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 59,000.00
Revenue, FY2025 · full 13-year series below
Revenue
Net income
The company lost 132642 cents on every revenue dollar this year.
Per share
USD -5.84
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-72.4%
Return on equity, FY2025
ROE
Operating margin-123601.7%
Net margin-132642.4%
Return on assets-58.6%
Each USD of equity lost 72 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−61.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−85.2%
−61.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 116.5M
total assets, end of FY2025
Total assetsUSD 116.5M
EquityUSD 83.0M
CashUSD 15.9M
Current ratio8.14×
Equity funds 71% of total assets.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.1
−0.1
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.1
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
·
·
Net income $B
−0.1
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−5.84
−20.91
−113.58
−4.43
·
·
·
−1.20
0.42
−1.87
−4.71
−5.48
−20.72
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−72.4
−50.1
·
−684.8
−354.2
−278.8
−76.7
−164.3
84.6
−247.9
·
·
·
Shares out B
0.02
0.01
0.00
0.00
0.01
0.08
0.04
0.04
0.03
0.01
0.01
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
34 of 34
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed